Cargando…
1248. Efficacy and Safety of Oral Ibrexafungerp in 41 Patients with Refractory Fungal Diseases, Interim Analysis of a Phase 3 Open-label Study (FURI)
BACKGROUND: Candida infections resistant to currently available antifungals are an emerging global threat. Ibrexafungerp is an investigational broad-spectrum glucan synthase inhibitor antifungal with activity against Candida and Aspergillus species, including azole- and echinocandin-resistant strain...
Autores principales: | Alexander, Barbara D, Cornely, Oliver, Pappas, Peter, Miller, Rachel, Vazquez, Jose A, Ostrosky-Zeichner, Luis, Spec, Andrej, Rautemaa-Richardson, Riina, Krause, Robert, Thompson III, George R, Morse, Caryn, Sanders, John W, Andes, David, Lyon, George, Marty, Francisco M, Silverman, Emily, Miceli, Marisa H, Patterson, Thomas F, Hoenigl, Martin, Azie, Nkechi, Angulo, David A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777495/ http://dx.doi.org/10.1093/ofid/ofaa439.1432 |
Ejemplares similares
-
123. Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI)
por: Pappas, Peter G, et al.
Publicado: (2021) -
871. Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI)
por: Thompson, George R, et al.
Publicado: (2022) -
P056 Oral Ibrexafungerp outcomes by fungal disease in patients from an interim analysis of a Phase 3 Open-label Study (FURI)
por: Prattes, Juergen, et al.
Publicado: (2022) -
Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections
por: Angulo, David A., et al.
Publicado: (2022) -
P057 All- cause mortality in patients with invasive Candidiasis or candidemia from an interim analysis of a Phase 3 Open-label Study (FURI)
por: Prattes, Juergen, et al.
Publicado: (2022)